Strand Life Sciences

What Strand Life Sciences does

Strand Life Sciences is a Bangalore-based, multi-omics solutions provider founded in 2000, operating as a subsidiary of Reliance Industries Limited. The company delivers an integrated platform spanning genomics, proteomics, transcriptomics, and spatial transcriptomics, with a portfolio of proprietary products including StrandNGS (NGS analysis software), PQRS (polygenic risk scoring), the scRNA Portal (single-cell RNA curation), and the StrandOmics clinical pipeline. Its technology stack combines AI-assisted variant interpretation, agentic AI for biomedical data curation, and a TileDB-integrated data architecture, supported by a CAP-accredited laboratory in India, HIPAA-compliant operations, and ISO 27001 certification.

Strand serves a hybrid customer base: global pharmaceutical and biotechnology enterprises seeking integrated multi-omics discovery, translational research, and biomarker validation programs (especially across India, South Asia, and West Asia); molecular diagnostics companies and US diagnostic/device firms requiring AI-driven somatic and germline variant interpretation, oncology panel reporting, and regulatory-compliant software; and, increasingly, the Indian healthcare system through affordable cancer screening and rare disease diagnostics. Strategic relationships include SOPHiA GENETICS (AI integration), Olink (high-throughput proteomics), TileDB (data infrastructure), and a tri-partite cancer biomarker testing program with Servier India and MedGenome.

The business model is predominantly professional services and B2B enterprise sales, with revenue generated from pharma biomarker discovery engagements, CAP-accredited lab services, software development for FDA/HIPAA-compliant omics platforms, and partnership-driven subsidized testing in India. Distribution leverages direct enterprise sales for global clients and the Reliance distribution network for consumer diagnostics in India, with a long-term strategic objective of reducing genomic test pricing to sub-Rs 1,000 to drive mass adoption similar to the Jio telecom disruption model.

Name

Strand Life Sciences

Legal name

Strand Life Sciences

Website

https://strandls.com

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Strand Life Sciences is a Bangalore-based, Reliance Industries-backed multi-omics company providing AI-driven genomics, proteomics, and clinical diagnostics software and lab services to global pharmaceutical firms, US diagnostic companies, and the Indian healthcare system, with a strategic push toward affordable consumer genomic testing.

Ownership category

akta.pro rank

Product category

Genomic Diagnostics & Bioinformatics Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (5132)

SIC

Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI)

akta.pro secondary industries

Bioinformatics & Multi-omics Analysis Software (HLAGAJAD), Transcriptomics & Gene Expression Profiling Services (HLAGANAE), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ)

Keywords

• Multi-omics bioinformatics
• Clinical genomic diagnostics
• Pharma biomarker discovery
• NGS data analysis
• AI variant interpretation

Headquarters

HQ city

Bangalore

HQ country

India

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Genomic Diagnostics Services: B2B services providing NGS and PCR diagnostics, biomarker testing, and clinical reporting to pharmaceutical companies, biotechnology organisations, and diagnostic laboratories.
2. Pharma and Biomarker Discovery: Clinical data and bioinformatics solutions for pharmaceutical companies for target discovery, translational research, and clinical research.
3. Software Development Services: Omics software development for managing and analyzing data, including HIPAA- and FDA-compliant software for medical devices and genomics tests.
4. CAP-Accredited Laboratory Services: Data generation services including single-cell, spatial transcriptomics and genomics from clinical samples in India-based CAP accredited laboratory.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

Strand Life Sciences provides integrated multi-omics solutions combining genomics, proteomics, transcriptomics, and spatial transcriptomics with AI-driven bioinformatics for pharmaceutical, biotechnology, and diagnostic customers. Core offerings include Pharma and Biomarker Discovery, High-Throughput Proteomics using the Olink Explore HT platform, NGS and PCR clinical diagnostics, software application development, and compliance services. Standalone software products include StrandNGS, the scRNA Portal, and the PQRS polygenic risk score platform.

Product overview

Strand Life Sciences operates as a multiomics solutions provider offering a portfolio of products and services that span the genomics and proteomics continuum. The core offerings include Pharma and Biomarker Discovery applications for drug target identification and translational research; High-Throughput Proteomics powered by the Olink Explore HT platform enabling analysis of over 5,400 protein biomarkers; and Diagnostics services combining PCR and NGS technologies for clinical molecular testing. Supporting the platform are software products including scRNA Portal for single-cell RNA analysis, PQRS for polygenic risk scoring, and StrandNGS for sequencing data analysis. Additional capabilities encompass Agricultural Technology solutions for plant genomics, Genomics Software Application Development for regulatory-compliant platforms, Compliance and Validation Services, Real-World Data Analysis for precision insights, and Biodiversity Informatics for social impact. The company also provides AI enablement capabilities including AI-Assisted Variant Interpretation, Data Organization and Therapeutic Applications of AI, and AI Guardrails, all built on a foundation of 25+ years of domain experience with over 300 specialists.

Differentiator

Problem solved

Functional benefit

Brands

• scRNA Portal: Portal for single-cell RNA curation and analysis
• PQRS
• StrandNGS
• CancerSpot

Products and services

• StrandNGS Next-generation sequencing data analysis software for visualization, statistical analysis, and biological interpretation of omics data, used by genomics researchers and clinical labs.
• scRNA Portal A portal for single-cell RNA sequencing data curation and analysis, enabling researchers to manage and analyze scRNA-seq data.
• PQRS (Polygenic Risk Score) Polygenic Risk Score platform for predicting disease risk based on genomic variations and multi-omics data integration, targeted at clinical and research customers.
• Pharma and Biomarker Discovery Applications Service enabling pharmaceutical companies to identify drug targets and biomarkers through integrated multi-omics data analysis, translational research, and clinical studies across therapeutic areas.
• High-Throughput Proteomics Service Proteomics service powered by the Olink Explore HT platform, enabling measurement of over 5,400 protein biomarkers from 2 microlitres of blood for multi-omics research and drug discovery. Targeted at pharmaceutical and biotechnology research customers.
• NGS and PCR Diagnostics Applications Clinical NGS and PCR diagnostic services for somatic and germline variant interpretation and oncology panel reporting, targeted at molecular diagnostics companies and clinical laboratories.
• Agricultural Technology Solutions Genomics solutions for plant and agricultural research, decoding plant omics for breeding and trait discovery applications.
• Genomics Software Application Development Custom software development services for omics data management and analysis, including HIPAA- and FDA-compliant platforms for medical devices and genomics tests. Targeted at US diagnostic and medical device companies.
• Compliance and Validation Services Regulatory compliance and validation services supporting clinical genomics and medical device software development, including FDA and HIPAA compliance requirements.
• Real-World Data Analysis Real-world patient data analytics combining clinical and omics datasets to deliver precision insights for pharmaceutical and healthcare customers.
• Biodiversity Informatics for Social Good Biodiversity informatics venture applying Strand's omics platforms to conservation and social impact research use cases.

Quantifiable outcome

• Over 5,400 protein biomarkers measurable from 2 microlitres of blood
• +2 more outcomes

Named customers6 records

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability10 records

Feature8 records

Partnerships

Four partnerships are on record, tiered core.

• OlinkcoreTechnology or Integration · 1 January 2026Deployment of Olink Explore HT platform for South Asia's first large-scale proteomics service. Enables measurement of 5,400+ protein biomarkers for multi-omics research and drug discovery.
• Servier IndiacoreStrategic or Co-development Partner · 1 November 2025Launched subsidized biomarker testing initiative for acute myeloid leukaemia (AML) and cholangiocarcinoma (CCA) across India. Government sector tests offered free, private sector costs significantly reduced. Aims to improve access to molecular diagnostics for underserved populations.
• MedGenomecoreStrategic or Co-development Partner · 1 November 2025Tri-partite partnership with Servier India and MedGenome for cancer biomarker testing. Strand provides genomics expertise and testing capabilities for AML and cholangiocarcinoma diagnostics in India.
• SOPHiA GENETICScoreTechnology or Integration · 1 June 2024Strategic partnership announced June 2024 to accelerate integration of AI platforms across the biotechnology sector. Combines SOPHiA GENETICS' AI capabilities with Strand's multi-omics expertise for enhanced biomarker discovery and clinical research.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• PierianDx (now Velsera): Velsera (formerly PierianDx) provides clinical genomics interpretation and reporting software, comparable to Strand's clinical NGS pipeline for US diagnostic and device companies.
• SOPHiA GENETICS: SOPHiA GENETICS operates a universal AI platform for genomics and radiomics, directly comparable to Strand's StrandOmics and AI-assisted variant interpretation. It is both a partner and a competitor in clinical multi-omics interpretation for global pharma and diagnostics labs.
• Congenica: Congenica delivers clinical genomics interpretation and rare disease diagnostics software, similar to Strand's clinical NGS reporting and variant interpretation capabilities for diagnostic labs.
• Fabric Genomics: Fabric Genomics provides AI-driven clinical NGS interpretation for hereditary disease and oncology, comparable to Strand's AI-Assisted Variant Interpretation and StrandOmics offerings for clinical reporting laboratories.
• MedGenome: MedGenome is an India- and US-based genomics diagnostics and research services company offering NGS-based clinical testing, biomarker discovery, and population genomics. It is a direct Strand peer in Indian clinical genomics and a co-partner in the Servier AML/CCA initiative.
• DNAnexus: DNAnexus provides a cloud-based genomics and biomedical data analysis platform with AI capabilities. Directly comparable to Strand's TileDB-integrated data architecture and multi-omics software platform ambitions for pharma R&D.

Broad incumbents

• QIAGEN Digital Insights (formerly Qiagen Bioinformatics): QIAGEN offers clinical genomics interpretation (QCI), sample technologies, and bioinformatics for pharma and molecular diagnostics. Comparable to Strand across both software products (StrandNGS vs. QCI) and pharma biomarker services.
• Illumina (DRAGEN / BaseSpace): Illumina is the dominant NGS instrument and secondary/tertiary analysis platform provider (DRAGEN, BaseSpace). While primarily an instrument vendor, its bioinformatics suite competes with Strand's interpretation capabilities, and Illumina is both a Strand customer and a powerful channel partner.

Others

• Olink Holding AB: Olink provides the proteomics platform (Explore HT) that Strand deploys as South Asia's first service. While a partner rather than competitor, Olink's roadmap and pricing directly shape Strand's proteomics services economics.

Emerging players

• GenomOncology: GenomOncology provides precision oncology workflow software for NGS-based somatic variant interpretation and clinical reporting — directly comparable to StrandOmics oncology panel reporting.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/strandlife
• Facebookfacebook.com/strandlife
• LinkedInlinkedin.com/company/strand-life-sciences

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Strand Life Sciences